论文部分内容阅读
临床试验表明,在神经纤维瘤患者中单独应用rh-IL-2或鼠抗GD_2与人的嵌合变异体ch14.18能通过激活LAK细胞或通过外周血单核细胞介导的ADCC作用杀死瘤细胞,通过基因工程将二者融合成为ch14.18-IL-2融合蛋白能特异地将rhIL-2导向肿瘤位点,抑制瘤细胞播散与生长的能力要比单独使用rhIL-2更有效。本研究选用人神经纤维瘤系SKN-AS细胞5×10~5/100μlPBS注入CB-17scid小鼠脾包膜下构建肝转移模型。1d后,对照组腹腔注射0.2mlPBS,其它注射4×10~7人LAK细胞后随机分组分别给予ch14.18、ch14.18+rhIL-2、ch14.18-IL-2治疗发现:对照组与仅给予LAK治疗的肝脏布满转移灶(>500个),肝增重3倍,二者间无显著性差异。LAK+ch14.18治疗组肝转移灶显著减少
Clinical trials have shown that ch14.18, a chimeric variant of rh-IL-2 alone or in combination with murine anti-GD2 and human chimeric in neurofibromatosis, can be killed by activating LAK cells or by peripheral blood monocyte-mediated ADCC Tumor cells, by genetic engineering to ch14.18-IL-2 fusion protein can specifically target rhIL-2 tumor sites, the ability to inhibit the spread and growth of tumor cells than rhIL-2 alone more effective . In this study, 5 × 10 ~ 5 / 100μl PBS of human neurofibromatosis SKN-AS cells were injected into the splenic capsule of CB-17scid mice to establish a liver metastasis model. After 1 day, 0.2 ml PBS was injected intraperitoneally into the control group, and other 4 × 10 ~ 7 LAK cells were injected into the control group and then randomly assigned to ch14.18, ch14.18 + rhIL-2, ch14.18-IL-2 treatment. Only the LAK-treated liver was covered with metastases (> 500), and liver weight gain was 3-fold, with no significant difference between the two. LAK + ch14.18 treatment group significantly reduced liver metastases